Envestnet Asset Management Inc. Reduces Stock Position in Johnson & Johnson $JNJ

Envestnet Asset Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,910,996 shares of the company’s stock after selling 31,512 shares during the quarter. Envestnet Asset Management Inc. owned about 0.20% of Johnson & Johnson worth $1,247,240,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. National Pension Service boosted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the period. IFP Advisors Inc lifted its stake in Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B boosted its position in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after buying an additional 2,563 shares during the period. Signal Advisors Wealth LLC grew its stake in shares of Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after buying an additional 6,539 shares in the last quarter. Finally, Gradient Investments LLC raised its holdings in shares of Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination estimated that approximately 87% of eligible relapsed/refractory multiple myeloma patients could reach mortality risk comparable to the general population. The analysis also projected nearly four times longer median survival versus standard care, supporting the long-term commercial potential of J&J’s oncology portfolio. MajesTEC-3 analysis
• Positive Sentiment: J&J’s recently approved ICOTYDE psoriasis treatment expands its immunology growth pipeline beyond oncology and MedTech. Its ongoing Phase 3 psoriatic arthritis program could provide an additional growth opportunity as STELARA sales decline after loss of exclusivity. ICOTYDE immunology push
• Positive Sentiment: Positive Phase 3 results for CAPLYTA in bipolar I mania strengthen the case that J&J’s Intra-Cellular acquisition can broaden the drug’s use beyond bipolar depression. Approval and commercial execution remain future catalysts. CAPLYTA bipolar study
• Neutral Sentiment: Analysts continue to favor J&J’s dividend durability and diversified pipeline, but the stock’s strong 12-month performance and elevated valuation may already reflect much of the expected improvement. Healthcare dividend roundup
• Negative Sentiment: Investor debate remains focused on whether portfolio streamlining, including a potential sale of the orthopedics business, can accelerate growth without sacrificing scale or future MedTech opportunities. The market’s reaction to OTTAVA also underscores the need for stronger execution in MedTech. Potential orthopedics divestiture

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.1%

NYSE:JNJ traded down $0.18 during mid-day trading on Wednesday, hitting $269.01. The stock had a trading volume of 6,371,746 shares, compared to its average volume of 8,034,880. Johnson & Johnson has a twelve month low of $175.74 and a twelve month high of $281.07. The stock has a 50-day simple moving average of $264.30 and a two-hundred day simple moving average of $247.03. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $648.28 billion, a PE ratio of 31.17, a PEG ratio of 2.57 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm posted $2.77 EPS. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HSBC raised their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Scotiabank reiterated an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Finally, Guggenheim upped their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $274.13.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.